{
    "organizations": [],
    "uuid": "4507e88507b2606fc46970b654977fee4846309a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-arcadia-biosciences-q1-revenue-fel/brief-arcadia-biosciences-q1-revenue-fell-79-percent-to-214000-idUSASC0A137",
    "ord_in_thread": 0,
    "title": "BRIEF-Arcadia Biosciences Q1 Revenue Fell 79 Percent To $214,000",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " in a minute BRIEF-Arcadia Biosciences Q1 Revenue Fell 79 Percent To $214,000 Reuters Staff\nMay 9 (Reuters) - Arcadia Biosciences Inc:\n* ARCADIA BIOSCIENCES ANNOUNCES FIRST-QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS * Q1 REVENUE FELL 79 PERCENT TO $214,000\n* ARCADIA BIOSCIENCES - “THE COMPANY IS WELL FUNDED TO BEGIN COMMERCIALIZATION ACTIVITIES FOR ITS PORTFOLIO OF HEALTH AND NUTRITION PRODUCTS”\n* QTRLY LOSS PER SHARE $4.86 Source text for Eikon: ",
    "published": "2018-05-09T23:31:00.000+03:00",
    "crawled": "2018-05-09T23:40:31.062+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "minute",
        "bioscience",
        "q1",
        "revenue",
        "fell",
        "percent",
        "reuters",
        "staff",
        "may",
        "reuters",
        "arcadia",
        "bioscience",
        "inc",
        "arcadia",
        "bioscience",
        "announces",
        "financial",
        "result",
        "business",
        "highlight",
        "q1",
        "revenue",
        "fell",
        "percent",
        "arcadia",
        "bioscience",
        "company",
        "well",
        "funded",
        "begin",
        "commercialization",
        "activity",
        "portfolio",
        "health",
        "nutrition",
        "product",
        "qtrly",
        "loss",
        "per",
        "share",
        "source",
        "text",
        "eikon"
    ]
}